טוען...
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
BACKGROUND: The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for...
שמור ב:
| הוצא לאור ב: | eLife |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
eLife Sciences Publications, Ltd
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8205484/ https://ncbi.nlm.nih.gov/pubmed/34085928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.69866 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|